- Home
- KLRS vs MMTX Comparison
KLRS vs MMTX Comparison
Compare KLRS & MMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLRS | MMTX |
|---|---|---|
| Founded | 2019 | 2025 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 89.8M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | KLRS | MMTX |
|---|---|---|
| Price | $3.90 | $10.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 43.5K | 17.1K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $165,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.03 | $9.89 |
| 52 Week High | $11.88 | $10.21 |
Technical Indicators
Market Signals| Indicator | KLRS | MMTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 55.05 |
| Support Level | $3.92 | $10.09 |
| Resistance Level | $4.37 | $10.21 |
| Average True Range (ATR) | 0.24 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 30.00 | 50.00 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About MMTX Miluna Acquisition Corp Class A Ordinary Share
Miluna Acquisition Corp is a blank check company.